Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Acute Myelogenous Leukemia
Drug:
cytarabine
(
DNA synthesis inhibitor
,
DNA-directed DNAP inhibitor
) +
cladribine
(
Purinergic receptor P1 agonist
) +
Nugraf (filgrastim biosimilar)
(
G-CSF stimulant
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Acute Myeloid Leukemia (Age >/=18 years)...THERAPY FOR RELAPSED/REFRACTORY DISEASE...Aggressive therapy for appropriate patients...Cladribine + Cytarabine + G-CSF +/- mitoxantrone or idarubicin
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login